HLA epitopes as viewed by antibodies: What Is it all about?

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1148-1154

  Tambur, A R ^a   Claas, F H J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

alloantibody; histocompatibility; immunobiology; immunogenetics; organ transplantation in general; translational research science

Indexed keywords

ANTIBODY; HLA ANTIGEN; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIBODY SPECIFICITY; ANTIGENICITY; B LYMPHOCYTE; DONOR; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETRANSPLANTATION; REVIEW; RISK REDUCTION; SENSITIZATION; ANTIGEN PRESENTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY TRANSPLANTATION; REOPERATION; TREATMENT OUTCOME;

ANTIBODIES; ANTIGEN PRESENTATION; EPITOPES; GRAFT REJECTION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; KIDNEY TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL; REOPERATION; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84928054313     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13192     Document Type: Review

References (46)

1. Dausset J,. [Iso-leuko-antibodies]. Acta Haematol 1958; 20: 156-166.
2. Van Leeuwen A, Eernisse JG, Van Rood JJ,. A new leucocyte group with two alleles: Leucocyte group five. Vox Sang 1964; 9: 431-446.
3. Payne R, Tripp M, Weigle J, Bodmer W, Bodmer J,. A new leukocyte isoantigen system in man. Cold Spring Harb Symp Quant Biol 1964; 29: 285-295.
4. Terasaki PI, Singal DP,. Human histocompatibility antigens of leukocytes. Annu Rev Med 1969; 20: 175-188.
5. Schwartz BD, Luehrman LK, Rodey GE,. Public antigenic determinant on a family of HLA-B molecules. J Clin Invest 1979; 64: 938-947.
6. Claas F, Castelli-Visser R, Schreuder I, van Rood J,. Allo-antibodies to an antigenic determinant shared by HLA-A2 and B17. Tissue Antigens 1982; 19: 388-391.
7. Fuller AA, Rodey GE, Parham P, Fuller TC,. Epitope map of the HLA-B7 CREG using affinity-purified human alloantibody probes. Hum Immunol 1990; 28: 306-325.
8. Starzl TE, Eliasziw M, Gjertson D, et al. HLA and cross-reactive antigen group matching for cadaver kidney allocation. Transplantation 1997; 64: 983-991.
9. Bjorkman PJ, Strominger JL, Wiley DC,. Crystallization and X-ray diffraction studies on the histocompatibility antigens HLA-A2 and HLA-A28 from human cell membranes. J Mol Biol 1985; 186: 205-210.
10. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC,. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512-518.
11. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC,. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989; 342: 692-696.
12. Zhang GL, Khan AM, Srinivasan KN, August JT, Brusic V,. MULTIPRED: A computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Res 2005; 33: W172-W179.
13. MacCallum RM, Martin AC, Thornton JM,. Antibody-antigen interactions: Contact analysis and binding site topography. J Mol Biol 1996; 262: 732-745.
14. Duquesnoy RJ, Marrari M,. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol 2002; 63: 353-363.
15. Duquesnoy RJ, Mulder A, Askar M, Fernandez-Vina M, Claas FH,. HLAMatchmaker-based analysis of human monoclonal antibody reactivity demonstrates the importance of an additional contact site for specific recognition of triplet-defined epitopes. Hum Immunol 2005; 66: 749-761.
16. Duquesnoy RJ,. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67: 847-862.
17. El-Awar NR, Akaza T, Terasaki PI, Nguyen A,. Human leukocyte antigen class I epitopes: Update to 103 total epitopes, including the C locus. Transplantation 2007; 84: 532-540.
18. Duquesnoy RJ, Marrari M,. Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens. Tissue Antigens 2009; 74: 117-133.
19. Lobashevsky AL, Senkbeil RW, Shoaf JL, et al. The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in AT PRA renal patients. Hum Immunol 2002; 63: 364-374.
20. Dankers MK, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004; 77: 1236-1239.
21. Duquesnoy RJ, Takemoto S, de Lange P, et al. HLAmatchmaker: A molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival. Transplantation 2003; 75: 884-889.
22. Duquesnoy RJ, Howe J, Takemoto S,. HLAmatchmaker: A molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 2003; 75: 889-897.
23. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II,. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 2004; 78: 190-193.
24. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013; 13: 3114-3122.
25. Marrari M, Conca R, Pratico-Barbato L, Amoroso A, Duquesnoy RJ,. Brief report: Why did two patients who type for HLA-B13 have antibodies that react with all Bw4 antigens except HLA-B13? Transpl Immunol 2011; 25: 217-220.
26. Cai J, Terasaki PI, Mao Q, et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947-2954.
27. Tambur AR, Buckingham M, McDonald L, Luo X,. Development of donor-specific and non-donor-specific HLA-DP antibodies post transplant: The role of epitope sharing and epitope matching. Clin Transpl 2006; 399-404.
28. Doxiadis II, Smits JM, Schreuder GM, et al. Association between specific HLA combinations and probability of kidney allograft loss: The taboo concept. Lancet 1996; 348: 850-853.
29. Taylor CJ, Dyer PA,. Maximizing the benefits of HLA matching for renal transplantation: Alleles, specificities, cregs, epitopes, or residues. Transplantation 1999; 68: 1093-1094.
30. Duquesnoy RJ, White LT, Fierst JW, et al. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation 1990; 50: 427-437.
31. Fuller TC, Fuller A,. The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder. Transplantation 1999; 68: 173-182.
32. Otten HG, Calis JJ, Kesmir C, van Zuilen AD, Spierings E,. Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation. Hum Immunol 2013; 74: 290-296.
33. Marrari M, Mostecki J, Mulder A, Claas F, Balazs I, Duquesnoy RJ,. Human monoclonal antibody reactivity with human leukocyte antigen class I epitopes defined by pairs of mismatched eplets and self-eplets. Transplantation 2010; 90: 1468-1472.
34. Duquesnoy RJ,. The antibody response to an HLA mismatch: A model for nonself-self discrimination in relation to HLA epitope immunogenicity. Int J Immunogenet 2012; 39: 1-9.
35. Cancro MP, Kearney JF,. B cell positive selection: Road map to the primary repertoire? J Immunol 2004; 173: 15-19.
36. Pradeu T, Carosella ED,. On the definition of a criterion of immunogenicity. Proc Natl Acad Sci USA 2006; 103: 17858-17861.
37. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS,. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90: 1117-1124.
38. Tambur AR, Leventhal JR, Zitzner JR, Walsh RC, Friedewald JJ,. The DQ barrier: Improving organ allocation equity using HLA-DQ information. Transplantation 2013; 95: 635-640.
39. Kosmoliaptsis V, Sharples LD, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ,. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2011; 91: 183-190.
40. Arnett KL, Adams EJ, Gumperz JE, et al. Expression of an unusual Bw4 epitope by a subtype of HLA-B8 [B0802]. Tissue Antigens 1995; 46: 316-321.
41. Kosmoliaptsis V, Dafforn TR, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ,. High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol 2011; 72: 1049-1059.
42. Tambur AR, Rosati J, Roitberg S, Glotz D, Friedewald JJ, Leventhal JR,. Epitope analysis of HLA-DQ antigens: What does the antibody see? Transplantation 2014; 98: 157-166.
43. Mulder A, Eijsink C, Kester MG, et al. Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies. J Immunol 2005; 175: 5950-5957.
44. Gebel HM, Bray RA,. HLA antibody detection with solid phase assays: Great expectations or expectations too great? Am J Transplant 2014; 14: 1964-1975.
45. Haarberg KM, Tambur AR,. Detection of donor-specific antibodies in kidney transplantation. Br Med Bull 2014; 110: 23-34.
46. Tambur AR, Claas FH,. Toward HLA epitope matching in clinical transplantation. Am J Transplant 2013; 13: 3059-3060.